A cell-permeable, orally bioavailable, blood-brain barrier-permeant MTIC [5-(3-methyltriazen-1-yl-)-imidazole-4-carboxamide] prodrug whose in vivo DNA alkylating activity is employed in anticancer therapy. MGMT (O6-methylguanine DNA methyl transferase) repairs TMZ-damaged DNA lesion by covalently transferring O6-methylation on guanine residues to a cysteine residue on the MGMT, forming the basis of TMZ-resistance in cancer treatment.
Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
その他情報
Neyns, B., et al. 2010. Cancer116, 2868. Marchesi, F., et al. 2007. Pharmacol. Res.56, 275. Chakravarti, A., et al. 2006. Clin. Cancer Res.12, 4738. Natsume, A., et al. 2005. Cancer Res.65, 7573. Jen, J.F., et al. 2000. Pharm. Res.17, 1284.
法的情報
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany